Case Study: MolMed Presents Process Development and Large-Scale CMP Production for Lentiviral (LV) Vectors

News & Events

Stay update

Case Study: MolMed Presents Process Development and Large-Scale CMP Production for Lentiviral (LV) Vectors ▾

Case Study: MolMed Presents Process Development and Large-Scale CMP Production for Lentiviral (LV) Vectors

MolMed organizes a webinar, with the collaboration of Phacilitate, entitled "Case Study: MolMed Presents Process Development and LargeScale GMP Production for Lentiviral (LV) Vectors" conducted by:

Luca Alberici, Chief Business Officer
Margherita Neri, Up-Stream Process Development Manager
Francesca Bellintani, Down-Stream Process Development Manager

Slide Deck1.87 MB

Subscribe to press releases

Contacts

Investor Relations & Communication Manager
Phone: +39 02 21277.205
E-mail: investor.relations@molmed.com

Investors

Contacts

Investor Relations & Communication Department
Telefono: +39 02 21277.321
E-mail: investor.relations@molmed.com

Investors

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.

News & Events

Stay update

Case Study: MolMed Presents Process Development and Large-Scale CMP Production for Lentiviral (LV) Vectors ▾